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ABSTRACT
Cyclin E is a major determinant in breast cancer initiation, progression, and chemotherapy response. Overexpression of cyclin E1 occurs in approximately 50% of breast cancers and this phenotype is associated with increased tumor aggressiveness, metastasis, hormone-independent growth, and poor patient survival. However, the molecular mechanism responsible for cyclin E alterations in breast cancers is not understood. In this research project, we explore the potential involvement of the protein phosphatase PP2A in causing cyclin E abnormalities in breast cancer. This will be achieved by identifying the PP2A holoenzyme complex that regulates cyclin E, evaluate the effects of PP2A activity knockdown on breast cancer progression, and screen for small molecules that can selectively inhibit PP2A regulation of cyclin E to attempt to correct for these alterations in breast cancers.
SUBJECT TERMS
Cyclin E1 degradation, PP2A protein phosphatase, SCFFbxw7 ubiquitin ligase, B55beta, B56delta YEAR 1 PROGRESS REPORT (W81XWH-11-1-0176) PP2A Regulation of Cyclin E in Breast Cancer: Therapeutic Implications INTRODUCTION: Cyclin E is a major determinant in breast cancer intiation, progression, and chemotherapy response [1] . Overexpression of cyclin E1 occurs in approximately 50% of breast cancers and this phenotype is associated with increased tumor aggressiveness, metastasis, hormone-independent growth, and poor patient survival [2] . However, the molecular mechanism responsible for cyclin E alterations in breast cancers is not understood. In this research project, we will explore the potential involvement of the protein phosphatase PP2A in causing cyclin E abnormalities in breast cancer. This will be achieved by identifying the PP2A enzyme complex that regulates cyclin E, evaluate the effects of PP2A activity knockdown on breast cancer progression, and screen for small molecules that can selectively inhibit PP2A regulation of cyclin E to attempt to correct for these alterations in breast cancers.
BODY: Year 1 concentrated on completing the tasks outlined in Aim1, which were designed to identify the composition of the PP2A holoenzyme that associates and regulates cyclin E phosphorylation. We have achieved all the tasks outlined in the approved Statement of Work (SOW). Tasks 1-3 (Aim 1): We successfully created expression vectors for tagged cyclin E for use in MudPIT analysis to identify interacting proteins and potentially the PP2A holoenzyme that targets cyclin E in breast cancer cells. The PP2A holoenzyme is a multi-subunit protein complex consisting of an A (structural), B (regulatory), and C (catalytic) subunit. The B subunit is believed to provide substrate specificity. MudPIT analysis was performed by collaborator James Wohlschlegel (UCLA). The results of this analysis identified a single PP2A holoenzyme subunit belonging to the Cα subunit. This data confirmed our preliminary data but did not identify the crucial B subunit.
Tasks 4-5 (Aim 1):
We then turned our focus to identifying the B subunit of PP2A using molecular techniques. Expression vectors were made that expressed Flag-or HA-tagged B subunits of the B and B' subclasses, which target most known PP2A substrates. These proteins were co-expressed with Myc-or Flag-tagged cyclin E and interactions in vivo determined by immunoprecipitation (IP) Western blot analysis (Task 5). The results of this analysis showed that at least 4 different B subunits, B55β, B55δ, B56β, and B56δ, strongly interacted with cyclin E1 in vivo (Fig. 1) . These results were also confirmed using reciprocal IP reactions. To functionally confirm these B-subunits in regulation of cyclin E stability, we knocked-down expression of these 4 B-subunits in various breast cancer cells lines using siRNA and analyzed the effects on cyclin E protein by Western blotting (Task 4). The results of this analysis showed that knockdown of B55β or B56δ had a profound effect on decreasing cyclin E1 levels, as predicted by our central hypothesis (Fig. 2) . Task 6 (Aim 1): To test the importance of PP2A B55β and PP2A B56δ in the regulation of cyclin E and potential therapeutic target in breast cancer we knocked-down expression of these B subunits in a panel of breast cancer cell lines. Remarkably, knockdown of either B subunit was found to induce a significant decrease in cyclin E protein levels in most cell lines tested (Fig. 3) . The only cell line in which this effect was not observed was Sum149PT, which we previously showed harbors a mutation of the SCF Fbxw7 ubiquitin ligase which mediates the ubiquitin-dependent proteolysis of cyclin E1. This data suggested that the effect on cyclin E1 was dependent on a functional degradation system, as predicted by our original hypothesis. Task 7 (Aim 1): To confirm the effects these B subunits on cyclin E stability, we co-expressed Myc-tagged cyclin E1 with the B-subunits and SCF Fbxw7 in HEK293T cells and performed cycloheximide-chase experiments. The results of this analysis showed that co-expression of the B subunit had a remarkable effect on stabilizing cyclin E1, protecting it from degradation by SCF Fbxw7 (Fig. 4) . Task 8 (Aim 1): We attempted to confirm the associations of cyclin E with the PP2A B subunits identified above using IP Western blot analysis. This analysis was complicated by the fact that endogenous cyclin E and PP2A B55β have a molecular weight around 50 kDa, which co-migrates with the IgG heavy chain on SDS-PAGE gels. Furthermore, no commercial antibodies for B55β and B56δ have been verified for IP. To Figure 2 . Evaluation of PP2A B-subunit panel on cyclin E levels in breast cancer. MDA-MB-231 cells were transfected with siRNA specific for B-subunits B55β, B55δ, B56β, and B56δ or control and cyclin E1 levels analyzed by Western blotting. Ku86 is shown as control. 
